Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

ABSTRACT: To evaluate the efficacy and safety of nimotuzumab in the treatment of EGFR-amplified advanced pan solid tumors (Lung/Esophageal/Gastric/Pancreatic /Colorectal / Head and neck Cervical).

DISEASE(S): Solid Tumor,Egfr Amplification,Neoplasms

PROVIDER: 90799 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

An open, single-center, Phase ? basket study of EGFR-based nimotuzumab combined with PD-1 in the treatment of advanced esophageal cancer, advanced pancreatic cancer, advanced head and neck cancer, and RAS-wt colorectal cancer

Project description:Interventions: Advanced esophageal cancer:PD-1 monoclonal antibody+nimotuzumab;Advanced pancretic cancer:PD-1 monoclonal antibody+nimotuzumab;Advanced head and neck tumor:PD-1 monoclonal antibody+nimotuzumab;RAS-WT-Advanced colorectal cancer:PD-1 monoclonal antibody+nimotuzumab Primary outcome(s): Objective response rate,ORR Study Design: Non randomized control

| 85179 | ecrin-mdr-crc

Study of Nimotuzumab to Treat Colorectal Cancer

Project description:Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced colorectal cancer.

| 2077668 | ecrin-mdr-crc

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

| 2709250 | ecrin-mdr-crc

Quantitative proteomic analysis of tumour tissues isolated from early and late stage human cervical cancer patients

Project description:Human papillomavirus (HPV) infection related malignancy remains a severe public health problem worldwide, although HPV prophylactic vaccine has been introduced 15 years ago . HPV-associated cancers comprise 29.1% of all 2.2 million infection-related cancers, including nearly 100% of cervical cancers1 and some head and neck cancers . Cervical cancers are the 3rd most common cancer in women worldwide, HPV16 and 18 account for about 70% of cervical cancers. Moreover, high-risk HPV infection, especially HPV16 infection, is related to a proportion of head and neck epithelial carcinoma in both developed and undeveloped countries. HPV related cancers are most severe in developing countries where HPV prophylactic vaccination rates are low.In this project, we use iTRAQ8plex-labelling proteomics to comparatively study the protein contents in the tumour tissues of early and late stage cervical cancer patietns.

2023-01-26 | PXD029103 | Pride

Transcription profiling of matching human primary head and neck squamous cell carcinomas and cervical lymph node metastases.

Project description:An experiment was performed to investigate the perservation of gene expression upon metastasis of primary head and neck squamous cell carcinomas to the cervical lymph node.

2006-10-23 | E-TABM-114 | biostudies-arrayexpress

Capturing the dynamic interactions between tumor and immune components of the tumor micro-environment is important for determining efficacy of anti-PD1 treatment [TBL]

Project description:RNA of tumor samples from 14 patients with head and neck squamous cell carcinoma treated anti-PD1 was analyzed on the nCounter system using the Pan cancer IO360 panel

2024-01-09 | GSE233980 | GEO

Identification of target genes of cancer-related microRNAs in human cancer

Project description:To identify target genes of cancer-related microRNAs in human cancer, several cell lines (bladder cancer, prostate cancer, renal cell carcinoma, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma) were subjected to Agilent whole genome microarrays.

2012-11-12 | GSE37119 | GEO

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND2)

Project description:Interventions: Group 1: one blood draw in cancer patients (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, uterine cancer, kidney/renal pelvis cancer, pancreatic cancer, liver cancer, stomach cancer, ovarian cancer, esophageal cancer, head and neck squamous cell cancer, thyroid cancer, small intestine cancer, cervical cancer, anal cancer, vulva cancer, testicular cancer) after study consent Group 2: one blood draw in healthy subjects Primary outcome(s): The primary objective of this study is to obtain clinically characterized, whole blood specimens from cancer and healthy subjects to develop and refine assays for cancer in the blood. Study Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other

| 93757 | ecrin-mdr-crc

The tumor suppressor gene rap1GAP is silenced by mir-101-mediated EZH2 overexpression in invasive squamous cell carcinoma

Project description:Rap1GAP is a critical tumor suppressor gene that is down-regulated in multiple aggressive cancers such as head and neck squamous cell carcinoma, melanoma and pancreatic cancer. However, the mechanistic basis of rap1GAP down-regulation in cancers is poorly understood. By employing an integrative approach, we demonstrate polycomb-mediated repression of rap1GAP that involves EZH2, a histone methyltransferase in head and neck cancers. We further concomitant down-regulation of rap1GAP in head and neck cancers. EZH2 represses rap1GAP by facilitating the trimethylation of H3K27, a mark of gene repression, and also hypermethylation of rap1GAP promoter. These results provide a conceptual framework involving a microRNA-oncogene-tumor suppressor axis to understand head and neck cancer progression. OSCC3-siRNA Non-Targeting Vs. siRNA EZH2 with dye-swap, HOK-Adeno CMV Vs. Adeno EZH2.

2011-11-02 | E-GEOD-28501 | biostudies-arrayexpress

Capturing the dynamic interactions between tumor and immune components of the tumor micro-environment is important for determining efficacy of anti-PD1 treatment [Post Culture_Metadata]

Project description:RNA extracted from the post 72 hour cultured tumor samples from 31 patients with head and neck squamous cell carcinoma treated Nivolumab and Nivolumab+Ipilimumab was analyzed on the nCounter system using the Pan cancer IO360 panel.

2024-01-09 | GSE234136 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data